Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
EA.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XJNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XJNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BR.5NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BR.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBF.8NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBF.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.29NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.1.29NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.5.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CM.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.1.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BL.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.75.9NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.75.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBHNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBHNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.1.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BL.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.78NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BQ.1.1.78NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.9.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.9.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.79.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.79.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.47NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.47NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.18NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BF.7.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAY.1.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XAY.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.55NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BQ.1.1.55NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BY.1.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BY.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.163NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.163NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.3 (Theta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
P.3 (Theta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.38.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.38.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAVNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XAVNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.1.4.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BE.1.4.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBC.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.343NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.343NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4.17 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used